(0.31%) 5 115.67 points
(0.31%) 38 357 points
(0.33%) 15 981 points
(-0.88%) $83.11
(5.77%) $2.03
(0.38%) $2 356.20
(0.50%) $27.67
(4.07%) $959.60
(-0.22%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.28%
@ $21.69
発行日: 14 2月 2024 @ 23:30
リターン: -11.39%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: -1.99 %
Live Chart Being Loaded With Signals
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 496 746 |
平均出来高 | 616 151 |
時価総額 | 1.73B |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.110 ) 2024-05-01 |
Last Dividend | $1.750 ( 2009-07-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.04 |
ATR14 | $0.0330 (0.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-14 | Muzzey Dale | Sell | 940 | Common Stock |
2024-04-14 | Verratti Mark | Sell | 1 076 | Common Stock |
2024-04-06 | Munk Natalie | Sell | 581 | Common Stock |
2024-03-14 | Leffler Scott J. | Buy | 46 905 | Common Stock |
2024-03-25 | Munk Natalie | Sell | 363 | Common Stock |
INSIDER POWER |
---|
52.41 |
Last 96 transactions |
Buy: 1 118 283 | Sell: 407 342 |
ボリューム 相関
Myriad Genetics Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Myriad Genetics Inc 相関 - 通貨/商品
Myriad Genetics Inc 財務諸表
Annual | 2022 |
収益: | $678.40M |
総利益: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2022 |
収益: | $678.40M |
総利益: | $476.40M (70.22 %) |
EPS: | $-1.390 |
FY | 2021 |
収益: | $690.60M |
総利益: | $493.00M (71.39 %) |
EPS: | $-0.350 |
FY | 2020 |
収益: | $638.60M |
総利益: | $452.50M (70.86 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Myriad Genetics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $1.750 | 2009-06-15 |
Last Dividend | $1.750 | 2009-07-01 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $3.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.02 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $3.50 | 10.20% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.374 | 1.500 | -7.47 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.239 | 1.200 | -7.96 | -9.55 | [0 - 0.3] |
returnOnEquityTTM | -0.350 | 1.500 | -5.00 | -7.49 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.268 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.963 | 0.800 | 9.04 | 7.23 | [0.8 - 2.5] |
cashRatioTTM | 0.363 | 1.500 | 9.09 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -93.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.846 | -1.692 | [0 - 20] |
debtEquityRatioTTM | 0.295 | -1.500 | 8.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.689 | 1.000 | 1.852 | 1.852 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.370 | 1.000 | -9.41 | -9.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.317 | 1.000 | -2.87 | -2.87 | [0.2 - 2] |
assetTurnoverTTM | 0.639 | 0.800 | 9.07 | 7.26 | [0.5 - 2] |
Total Score | -0.0149 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.42 | 1.000 | -0.648 | 0 | [1 - 100] |
returnOnEquityTTM | -0.350 | 2.50 | -3.21 | -7.49 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.692 | 2.00 | -0.564 | -1.692 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.782 | 2.00 | -0.261 | -0.521 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.289 | 1.500 | -5.26 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0870 | 1.000 | -4.68 | 0 | [0.1 - 0.5] |
Total Score | -2.29 |
Myriad Genetics Inc
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。